A post hoc analysis of data from the PALISADE trial has shown that plozasiran 25 or 50 mg s.c. quarterly for 12 months reduces recurrent pancreatitis in patients with familial chylomicronaemia syndrome (FCS) with a history of acute pancreatitis (AP) and the most extreme hypertriglyceridaemia.
TRL-C level may indicate fibrate benefit for atherosclerosis risk
Statin-treated individuals with elevated triglyceride-rich lipoprotein cholesterol (TRL-C) may be more likely to benefit from additional fibrate treatment, according to results of a study of 67,662 statin-treated adults without baseline atherosclerotic cardiovascular disease (ASCVD) from the Korean National Health Insurance Service cohort.
New ACC/AHA guidelines highlight importance of hypertriglyceridaemia management
New dyslipidaemia guidelines drawn up by the American College of Cardiology and the American Heart Association (ACC/AHA) incorporate new and updated recommendations for atherosclerotic cardiovascular disease (ASCVD) risk assessment in patients with elevated TG, and for the management of hypertriglyceridaemia (HTG).
Pemafibrate may improve liver fibrosis in MASLD
Pemafibrate may improve liver fibrosis, lipid metabolism and liver enzyme levels, according to results of a retrospective study of magnetic resonance elastrography (MRE) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridaemia (HTG).1
Olezarsen reduces need for health services in FCS
Olezarsen reduces all-cause health services utilisation and improves treatment experience for patients with familial chylomicronaemia syndrome (FCS). This is the finding from a recently published resource utilisation analysis of results from the Balance trial of olezarsen in patients with genetically identified FCS.
SHR-1918 shows promise in homozygous FH
The ANGPTL3-targeting agent, SHR-1918, significantly reduced LDL-C, TG, apoB and other atherogenic lipids in patients with homozygous familial hypercholesterolemia (HoFH) in a single arm, Phase 2 non-randomised study carried out at eight sites in China.
